AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

ROIV · NASDAQ · Biotechnology

Roivant Sciences (ROIV)

Develops immunology medicines and delivery technologies through focused Vant subsidiaries.

$38.35

After hours+0.13 (+0.34%)

At close$38.22(−1.97%)

In millions of USD, except per-share figures

In millions	Q2 FY23Sep 2023	Q3 FY23Dec 2023	Q4 FY23Mar 2024	Q1 FY24Jun 2024	Q2 FY24Sep 2024	Q3 FY24Dec 2024	Q4 FY24Mar 2025	Q1 FY25Jun 2025	Q2 FY25Sep 2025	Q3 FY25Dec 2025	Q4 FY25Mar 2026	Q1 FY26Jun 2026
Revenue	4	16	29	8	4	9	8	2	2	2	3	1
Cost of revenue	0	0	4	0	0	0	0	0	0	1	0	0
Gross profit	3	15	25	8	4	9	7	2	1	1	2	1
	217	−5,112	291	110	346	283	292	287	308	340	357	367
Research & development	115	108	121	121	143	142	145	153	165	165	199	202
	89	128	170	100	203	142	147	134	143	175	158	166
General & administrative	89	128	0	100	203	142	147	134	143	175	158	166
Other expenses	14	−5,348	0	−110	0	0	0	0	0	0	0	0
Operating income	−214	5,127	−266	−102	−342	−274	−285	−285	−306	−339	−355	−366
	−28	26	75	83	117	40	82	16	147	49	809	71
Interest income	14	32	83	72	70	62	55	48	45	43	41	37
Interest expense	9	9	—	13	0	0	0	0	0	0	0	0
Other non-operating income	−14	5,348	−82	110	−117	−40	−82	−16	−147	−49	−809	−71
Income before tax	−241	5,154	−191	−20	−224	−235	−203	−269	−159	−290	454	−295
Income tax expense	3	22	−9	12	12	−26	49	5	7	23	98	−4
Net income from continuing operations	−245	5,131	−182	−32	−237	−209	−252	−274	−166	−314	356	−291
Discontinued operations	−86	−59	0	89	−43	327	0	0	0	0	0	0
Net income	−304	5,096	−151	95	−230	169	−206	−223	−114	−266	303	−190
EPS, basic	−$0.40	$6.37	−$0.19	$0.13	−$0.31	$0.23	−$0.29	−$0.33	−$0.17	−$0.38	$0.43	−$0.26
EPS, diluted	−$0.40	$6.03	−$0.19	$0.12	−$0.31	$0.23	−$0.29	−$0.33	−$0.17	−$0.38	$0.37	−$0.26
Weighted average shares, basic	770	801	803	736	735	723	707	680	681	697	702	721
Weighted average shares, diluted	770	844	803	782	735	723	707	680	681	697	812	721
EBITDA	−194	−216	−179	−208	−220	−232	−202	−268	−158	−290	455	−288
Depreciation & amortization	6	5	5	5	5	3	1	1	1	1	1	6
EBIT	−200	−221	−184	−213	−224	−235	−203	−269	−159	−290	454	−295